News from targetedonc.comFollowNews from targetedonc.comSee all of targetedonc.com’s headline news. Compare how the top news stories are covered by left-wing and right-wing news sources.We’ve aggregated 215 of targetedonc.com’s headlines and news stories over the past 3 months. Ground News rates targetedonc.com’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. Is targetedonc.com credible or reliable? Our Factuality score answers both of those questions. When it comes to targetedonc.com, we’ve assigned a unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.Follow See all of targetedonc.com’s headline news. Compare how the top news stories are covered by left-wing and right-wing news sources. We’ve aggregated 215 of targetedonc.com’s headlines and news stories over the past 3 months. Ground News rates targetedonc.com’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. Is targetedonc.com credible or reliable? Our Factuality score answers both of those questions. When it comes to targetedonc.com, we’ve assigned a unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check. Information about targetedonc.comWhere is targetedonc.com located?targetedonc.com's WebsiteMedia Bias RatingsDo you diasgree? Edit biasLearn more about Media Bias Ratings.FactualityAverage Factuality Rating: UnknownLearn more about Factuality Ratings.Top targetedonc.com NewsEli Lilly · United StatesLilly gets traditional FDA approval for Retevmo for thyroid cancer (NYSE:LLY)100% Right coverage: 1 sourcesEli Lilly (LLY) has received traditional approval for its drug Retevmo for the treatment of medullary thyroid cancer with a RET mutation. Read more here.See the StoryAstraZeneca · United StatesFDA Expands Approval of Osimertinib in Lung Cancer100% Center coverage: 1 sourcesThe FDA has approved osimertinib (Tagrisso) for locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) following chemoradiotherapy, theSee the StoryCancer · United StatesBeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ CancersFDA panel supports TEVIMBRA for advanced esophageal and gastric cancers with high PD-L1 expression. BeiGene's Phase 3 trials show promising results, but limitations apply. Learn more about this potential treatment option.See the StoryLatest News StoriesTopics Most Covered by targetedonc.comCancerBreast CancerFDAAstraZenecaESACancerBreast CancerFDASources Covering Similar Topicsonclive.comcancernetwork.comPharmacy Timescuretoday.comajmc.comonclive.comcancernetwork.comPharmacy TimesSuggest a sourceLooking for a source we don't already have? Suggest one here.You've scrolled to the bottom of the feed, there are no more stories.Breaking News Topics Related to targetedonc.comGeneva, SwitzerlandBreast CancerSwitzerlandCalifornia, United StatesMarylandCancerUnited States
